Latest Breaking News On - Poster hall - Page 3 : vimarsana.com

MyOme Presents New Data: Improved 10-year Risk Prediction of Coronary Artery Disease through Polygenic Risk Scores Integrated with Clinical Factors Showcased at the American Society of Human Genetics Annual Meeting

MyOme Presents New Data: Improved 10-year Risk Prediction of Coronary Artery Disease through Polygenic Risk Scores Integrated with Clinical Factors Showcased at the American Society of Human Genetics Annual Meeting
lelezard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lelezard.com Daily Mail and Mail on Sunday newspapers.

Menlo parkUnited statesAkash kumarAmerican society of human geneticsAmerican society of human genetics annual meetingMyome incClinical laboratory improvement amendmentsOme presents new dataRisk predictionCoronary artery diseasePolygenic risk scores integratedClinical factors showcasedAmerican societyHuman genetics annualSouth asianHuman genetics

Immunocore announces upcoming poster presentations at SITC Annual Meeting 2023 and SMR Congress 2023

Immunocore announces upcoming poster presentations at SITC Annual Meeting 2023 and SMR Congress 2023
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomWestern australiaMarlana orloffClayton robertsonAlexandra ikeguchiImmunocore immOmid hamidMarcus butlerDiwakar davarRyan sullivanAleksandra raczkaEuropean unionImmunocore holdingsExchange commission onHead of communications

Pliant Therapeutics Announces Three Presentations at the

SOUTH SAN FRANCISCO, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company and.

San diego convention centerUnited statesSan diegoChristopher keenanEuropean medicines agencyDrug administrationCorporate communicationsPliant therapeutics incAnnual meetingPoster hallPliant therapeuticsFast track designationOrphan drug designationPrivate securities litigation reform actFinancial conditionQuarterly report

TriSalus Life Sciences Announces Late Breaker and Additional Data Presentations on Liver Metastases and Pancreatic Cancer at the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting

TriSalus Life Sciences® Inc., , an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors, today announced.

United statesSan diegoChandrac ghoshSapanp patelMichaels leeUniversity of texas md anderson cancer centerTrisalus life sciencesUveal melanoma programSociety for immunotherapy of cancerExchange commissionTrisalus lifeAnnual meetingBreaker oral presentationClinical activityImmune checkpoint inhibitionMetastatic uveal melanoma liver metastasis

Therini Bio Announces Interim Results from the Phase 1

- THN391 was found to be safe and well-tolerated THN391 demonstrated a prolonged half-life and dose proportional Cmax levels The data will be.

United statesUniversity of california san franciscoUniversity of california san diegoJeffrey stavenhagenTherini bioEli lillyKaterina akassoglouLeslie schulzeAlzheimer drug discovery foundationBoston park plaza hotelSv health investor impact medicine fundDementia discovery fundTherini bio incClinical developmentVentures fundClinical trials